Søby, S. (2025) “Pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multi-institutional DAHANCA cohort study”, Acta Oncologica, 64, pp. 1269–1275. doi: 10.2340/1651-226X.2025.44327.